Grifols (GRFS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Grifols (GRFS) is Neutral.

The composite score behind that read is +0.13, weighing +0.41 of bullish evidence against -0.16 bearish.

Grifols last closed at $7.46, +0.67% on the session.

Against the IVW growth benchmark the position is -0.13% over the forecast window.

The read is built from 15 underlying insights — 5 bullish and 10 bearish.

Agreement across those insights is 33%.

11 graded predictions for GRFS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Grifols in the 85th percentile on valuation and the 56th percentile on return on equity, where 100 is best.

Grifols is classified under Health Care / Biotechnology, with a market capitalisation of $1.91B.

StockMap tracks Grifols as the 92nd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Grifols ranks 36th of 381 in the group, against a group median of -0.08.